Navigation Links
Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Date:12/7/2008

requires extensive monitoring and poses potentially serious drug and food interactions," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Limited. "The start of our Phase III trial marks an important milestone in the clinical development of DU-176b and we hope this compound will prove to be another successful treatment in our cardiovascular portfolio."

About Atrial Fibrillation

Atrial fibrillation (AF) is an irregular heartbeat caused when the upper chambers of the heart (the atria) beat inconsistently and rapidly. When this happens, blood can become stagnant near the walls of the atria and form blood clots. These blood clots can break off and travel through the blood stream to the brain where they can block blood vessels possibly causing a stroke. These clots can also cause damage to other organs in the body by blocking peripheral arteries.

About 90,000 strokes in the U.S. are caused by atrial fibrillation.(1) Patients with atrial fibrillation have five times higher risk of having a stroke.(2) These patients also tend to have more serious first strokes than patients without atrial fibrillation, resulting in higher mortality rates and longer hospital stays.(1)

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism. Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition and was the first company to test these compounds in humans.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that a
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
8. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... Nov. 20, 2014  Market research firm Kalorama information says ... The Buy, in the medical device industry.  The firm ... will produce just 3% growth this year, which led ... of product lines and entrance by acquisition into new ... medical devices, The Global Market for Medical Devices, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... HONG KONG, Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, ... acquire the remaining interests in the Group,s Chinese ... HK$90 million in shares.  Upon completion of the ...
... Calif., Feb. 24, 2011 Amgen (Nasdaq: AMGN ... 3 head-to-head trial that compared XGEVA ™ (denosumab) to ... skeletal-related events (SREs) in 1,901 men with prostate cancer and ... met its primary and secondary endpoints and demonstrated XGEVA,s superiority ...
Cached Medicine Technology:Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
(Date:11/22/2014)... NC (PRWEB) November 23, 2014 Cancer ... found a connection between intercellular communication tunnels and the ... read the full story on the Surviving Mesothelioma ... Center and the University of Minnesota have just released ... carry information and materials between cells. They found that ...
(Date:11/22/2014)... A classic black prom dress will never go ... suppliers, has unveiled its new items of black prom ... at a big discount, up to 70% off. People throughout ... new black prom dresses, made with the best materials, can ... of all customers, the company provides these beautiful outfits in ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding ... the business offers a wide range of special occasion ... allowing them to create multiple looks easily. , According ... collection of chic wedding dresses has been prepared for ... discounted rates now. Dylan Queen can always create what ...
(Date:11/22/2014)... Discount-Dress.com is an important company in the dress industry. ... company’s online market share by a series of promotions. Recently, ... announced a bridesmaid dress promotion for the new year 2015. ... the dresses from this company are not only of high ... very good at manufacturing wedding dresses. Customers prefer to choose ...
(Date:11/22/2014)... "My friend went in for a mammogram ... said an inventor from Cambria Heights, N.Y. "To add ... second time because the first results were inaccurate. Her ... patent-pending MAMO EASY to offer a more comfortable way ... patient from the pain normally involved with this procedure. ...
Breaking Medicine News(10 mins):Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2
... Storage and to Advance VSEL Research, NEW YORK, ... is pioneering the pre-disease collection, processing and long-term,storage of ... that,it has signed a collection center agreement with the ... Robin Smith, MD MBA, NeoStem,s Chairman and Chief Executive ...
... May 27 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... dollars from Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ... the recently announced transaction,between Takeda Pharmaceutical Company Limited ... receive portions of future milestone and royalty,payments. This ...
... communities save time and money accepting automatic ... payments direct from resident bank accounts, PORTLAND, ... it,has added PaySimple, the leading provider of on-demand ... to help simplify resident billing,and collection for assisted ...
... join the Urban League of,Philadelphia for FREE Open House Clinics ... ages 19 and under, in,Pennsylvania,s Children,s Health Insurance Program (CHIP). ... the Urban League of Philadelphia, 121,S. Broad Street (between Chestnut ... Wednesday, May 28th, 6pm - 8pm Wednesday, ...
... at UCLA have identified a type of leukemia stem cell ... normal blood stem cells to become cancerous. , The discovery ... cells, attacking the disease at its very root and killing ... cells. The study appears in the May 22, 2008 issue ...
... Inc. (Nasdaq: EVVV ) today,announced that Robert Palmisano, ... the Goldman Sachs Twenty-Ninth Annual Global,Healthcare Conference on Tuesday, ... and 1:00 p.m. CT). The Goldman Sachs Twenty-Ninth Annual ... Niguel in,Dana Point, California., To access the webcast, ...
Cached Medicine News:Health News:NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital 2Health News:NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital 3Health News:Isis to Receive $4.6 Million From Alnylam 2Health News:Isis to Receive $4.6 Million From Alnylam 3Health News:Vigilan Offers PaySimple to Simplify Resident Billing and Collection 2Health News:Does Your Child Have Health Insurance? Urban League of Philadelphia Announces Free Open Houses for CHIP Enrollment 2Health News:UCLA researchers identify leukemia stem cells 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: